To mark the launch of the ground-breaking Quantidex® QPCR BCR-ABL IS Kit, manufacturer Asuragen held a series of three webinars. We covered the first two webinars here and here, so head there first if you haven’t already seen them.
The third and final webinar, outlined below, examines the clinical expectations for BCR-ABL monitoring against the backdrop of the launch of this new product.
The third webinar focuses on how the QuantideX® qPCR BCR-ABL IS Kit provides a simple, sensitive, and scalable BCR-ABL monitoring solution for a laboratory.
It is delivered by Guy Wayne Novotny PhD, Director of Hematology / Molecular Pathology Departments at Herlev Hospital in Denmark.
The webinar examines:
- The effect of evolving patient management on BCR-ABL testing expectations
- The motivation for adopting the QuantideX qPCR BCR-ABL IS Kit
- How the assay enables the lab to meet the needs of clinicians, patients, and the laboratory — both today and tomorrow.
To view the webinar, please click the below image (opens on a new page):
QuantideX BCR-ABL IS Kit provides labs with a robust and reliable method for monitoring leukaemia patients, also allowing them to keep pace with the advances in TKI therapy.
It is seen as a major breakthrough for labs dealing with the monitoring of leukaemia patients, offering reduced complexity and optimised workflow without losing high-quality performance.
You can read about the QuantideX® qPCR BCR-ABL Portfolio in more detail here – but we would strongly recommend listening to/watching the fascinating webinars, too, which are delivered by some of the world’s leading figures in oncology and haematology research and product development.
For more information about the QuantideX® qPCR BCR-ABL Portfolio, contact VH Bio today.